PF-06821497
Sponsors
Pfizer Inc., Pfizer
Conditions
METASTATIC CASTRATION RESISTANT PROSTATE CANCERMETASTATIC CASTRATION-SENSITIVE PROSTATE CANCERMetastatic Castrate Resistant Prostate Cancer (mCRPC)Metastatic Castration-Resistant Prostate Cancer
Phase 3
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
RecruitingNCT06551324
Start: 2024-10-21End: 2028-10-29Target: 600Updated: 2026-03-04
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
RecruitingNCT06629779
Start: 2024-10-22End: 2028-11-30Target: 900Updated: 2026-03-25
C2321014: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)
RecruitingCTIS2024-511650-50-00
Start: 2025-01-17Target: 205Updated: 2025-12-09
C2321003: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)
RecruitingCTIS2024-511652-40-00
Start: 2025-02-05Target: 328Updated: 2025-12-18
C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)
Not yet recruitingCTIS2024-519369-24-00
Target: 434Updated: 2026-01-12